Gene therapy bolsters Parkinson’s drug benefits in pre-clinical study
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
List view / Grid view
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
Scientists revealed five proteins that cause blood vessel damage in COVID-19 patients, potentially leading to new drug targets.
Moderna and Metagenomi have announced a collaboration to jointly create next-generation in vivo gene editing therapeutics.
A new high-resolution virtual microscopy technique enables the rapid visualisation of tissue, paving the way for histopathology analysis during surgery.
Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.
Scientists have discovered a novel pathway and enzyme that causes thrombosis in chronic kidney disease (CKD) patients, indicating a new drug target.
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
Turning off NHE6 in mice in pre-clinical studies prevented amyloid beta aggregation, a key feature of Alzheimer's disease, pointing to new therapies.
Scientists have used nuclear magnetic resonance (NMR) spectroscopy to investigate the protein p53, which they say could advance cancer studies.
A new grant will allow an international team to determine if scent-processing nerves in the nose play a role in the development of Parkinson's and could aid in the development of novel therapeutics.
Scientists have used several machine learning models to predict bacterial gene exchange, which could reveal novel antibiotic targets.
A new label-free technique has been developed for molecularly specific exosome biosensing in diagnostics and biomarker detection.
Professor Ulrich G Steidl received the National Institute of Cancer's Outstanding Investigator Award to study myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).
The small molecule successfully targeted the C9orf72 gene that causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Researchers used Raman spectroscopy to monitor immunotherapy response in mice, potentially improving cancer treatments in the future.